Clinimetric evaluation of the bath ankylosing spondylitis metrology index in a controlled trial of pamidronate therapy

Journal of Rheumatology

Volumn 31, Issue 12, 2004, Pages 2422-2428

  Jauregui, Edwin ^a   Conner Spady, Barbara ^a   Russell, Anthony S ^a   Maksymowych, Walter P ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b ALBERTA ENVIRONMENT AND PARKS   (Canada)

Author keywords

Ankylosing spondylitis; Pamidronate; Responsiveness; Spinal mobility

Indexed keywords

INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BATH ANKYLOSING SPONDYLITIS METROLOGY INDEX; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; DOUBLE BLIND PROCEDURE; FEMALE; HIP; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; NON INVASIVE MEASUREMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SPINE MOBILITY;

ADULT; AGED; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PAIN MEASUREMENT; PROBABILITY; RANGE OF MOTION, ARTICULAR; REFERENCE VALUES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

EID: 10044263345     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Van der Heijde D, Calin A, Dougados M, Khan MA, van der Linden S, Bellamy N. Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. J Rheumatol 1999;26:951-4.
2. Bellamy N. Clinimetric concepts in outcome assessment: The OMERACT filter. J Rheumatol 1999;26:948-50.
3. Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 1994;21:1694-8.
4. Chung C, Jauregui E, Spady B, Mallon C, Russell AS, Maksymowych WP. The Edmonton Ankylosing Spondylitis Metrology Index (EDASMI): Validation of a new composite index of spinal and hip mobility [abstract]. Arthritis Rheum 2003;48 Suppl:S176.
5. Van den Bosch F, Kruithof E, Baeten D, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor a (infliximab) versus placebo in active spondyloarthropathy. Arthritis Rheum 2002;46:755-65.
6. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet 2002;359:1187-93.
7. Heikkila S, Viitanen JV, Kautiainen H, Kauppi M. Sensitivity to change of mobility tests; effect of short term intensive physiotherapy and exercise on spinal, hip, and shoulder measurements in spondyloarthropathy. J Rheumatol 2000;27:1251-6.
8. Auleley GR, Benbouazza K, Spoorenberg A, et al. Evaluation of the smallest detectable difference in outcome or process variables in ankylosing spondylitis. Arthritis Rheum 2002;47:582-7.
9. Jones SD, Porter J, Garrett SL, Kennedy LG, Whitelock H, Calin A. A new scoring system for the Bath Ankylosing Spondylitis Metrology Index (BASMI) [letter]. J Rheumatol 1995;22:1609.
10. Maksymowych WP, Jhangri GS, Fitzgerald A, et al. A six-month randomized, controlled, double-blinded, dose response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of NSAID-refractory ankylosing spondylitis. Arthritis Rheum 2002;46:766-82.
11. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.
12. Husted JA, Cook RJ, Farewell VT, Gladman DD. Methods for assessing responsiveness: a critical review and recommendations. J Clin Epidemiol 2000;53:459-68.
13. Anderson JJ, Chernoff MC. Sensitivity to change of rheumatoid arthritis clinical trial outcome measures. J Rheumatol 1993;20:535-7.
14. Cohen J, Cohen P. Applied multiple regression/correlation analysis for the behavioral sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1983.
15. Haibel H, Brandt J, Rudwaleit M, Sorensen H, Sieper J, Braun J. Treatment of active ankylosing spondylitis with pamidronate. Rheumatology Oxford 2003;42:1018-20.
16. Terpos E, Palermos J, Tsionos K, et al. Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma. Eur J Haematol 2003;71:471-2.
17. Roberts WN, Larson MG, Liang MH, Harrison RA, Barefoot J, Clarke AK. Sensitivity of anthropometric techniques for clinical trials in ankylosing spondylitis. Br J Rheumatol 1989;28:40-5.
18. Pile KD, Laurent MR, Salmond CE, Best MJ, Pyle EA, Moloney RO. Clinical assessment of ankylosing spondylitis: a study of observer variation in spinal measurements. Br J Rheumatol 1991;30:29-34.
19. Viitanen JV, Kokko M-L, Lehtinen K, Suni J, Kautiainen H. Correlation between mobility restrictions and radiological changes in ankylosing spondylitis. Spine 1995;20:492-6.
20. Gauvin M, Riddle D, Rothstein J. Reliability of clinical measurements of forward bending using the modified finger-to-floor method. Phys Ther 1990;70:443-7.
21. O'Driscoll SL, Jayson MIV, Baddeley H. Neck movements in ankylosing spondylitis and their responses to physiotherapy. Ann Rheum Dis 1978;37:64-6.
22. Tomlinson MJ, Barefoot J, Dixon ASTJ. Intensive in-patient physiotherapy courses improve movement and posture in ankylosing spondylitis. Physiotherapy 1986;5:238-40.
23. Wordsworth BP, Pearcy MJ, Mowat AG. In-patient regime for the treatment of ankylosing spondylitis: an appraisal of improvement in spinal mobility and the effect of corticotrophin. Br J Rheumatol 1984;23:39-43.
24. Corkill MM, Jobanputra P, Gibson T, MacFarlane DG. A controlled trial of sulphasalazine treatment of chronic ankylosing spondylitis: Failure to demonstrate a clinical effect. Br J Rheumatol 1990;29:41-5.
25. Dougados M, van der Linden S, Leirisalo-Repo M, et al. Sulphasalazine in the treatment of spondyloarthropathy. Arthritis Rheum 1995;38:618-27.
26. Clegg DO, Reda DJ, Weisman MH, et al. Comparison of sulphasalazine and placebo in the treatment of ankylosing spondylitis. Arthritis Rheum 1996;39:2004-12.
27. Kirwan J, Edwards A, Huitfeldt B, Thompson P, Currey H. The course of established ankylosing spondylitis and the effects of sulphasalazine over 3 years. Br J Rheumatol 1993;32:729-33.
28. Taylor HG, Beswick EJ, Dawes PT. Sulphasalazine in ankylosing spondylitis. A radiological, clinical and laboratory assessment. Clin Rheumatol 1991;10:43-8.
29. Nissila M, Lehtinen K, Leirisalo-Repo M, Luukkainen R, Mutru O, Yli-Kerttula U. Sulfasalazine in the treatment of ankylosing spondylitis: A twenty-six-week, placebo-controlled clinical trial. Arthritis Rheum 1988;31:1111-6.
30. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor a. N Engl J Med 2002;346:1349-56.
31. Davis JC Jr, van der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis. Arthritis Rheum 2003;48:3230-6.